Cantor Fitzgerald analyst Louise Chen reinstated coverage of Humanigen with a Neutral rating and $0.15 price target. Humanigen has has shifted its focus to the development of lenzilumab in chronic myelomonocytic leukemia, in acute graft versus host disease, and in combination with CAR-T therapies, and while there is still a lot of value to be unlocked for shares, Chen remains on the sidelines until earnings visibility improves, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly